Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act
2026 · 2nd Quarter (Apr 1 - June 30)
BRIDGEBIO PHARMA, INC.
Filed by BRIDGEBIO PHARMA, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- Not reported
- Expenses
- $500,000.00
- Registrant
- BRIDGEBIO PHARMA, INC.
- Client
- BRIDGEBIO PHARMA, INC.
- Filing UUID
- 0f0fe3ec-de79-47ba-baba-96603250aabf
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.